NasdaqGS - Nasdaq Real Time Price USD

Atara Biotherapeutics, Inc. (ATRA)

0.6974 +0.0364 (+5.51%)
At close: April 22 at 4:00 PM EDT

Key Executives

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Dr. Pascal Touchon D.V.M. President, CEO & Director 1.08M -- 1963
Mr. K. Amar Murugan Executive VP & Chief Legal Officer 618.52k -- 1976
Mr. Eric Hyllengren Executive VP & Chief Financial Officer -- -- 1976
Dr. Anhco Nguyen Ph.D. Executive VP and Chief Scientific & Technical Officer -- -- 1973
Alex Chapman Vice President of Corporate Communications & Investor Relations -- -- --
Ms. Jill Henrich Executive VP and Global Head of Regulatory Affairs & Quality -- -- 1963
Mr. Dan Maziasz Executive VP & Chief Business Officer -- -- --
Ms. Rajani Dinavahi M.D. Senior VP & Chief Medical Officer -- -- --

Atara Biotherapeutics, Inc.

2380 Conejo Spectrum Street
Suite 200
Thousand Oaks, CA 91320
United States
805 623 4211 https://www.atarabio.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
225

Description

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.

Corporate Governance

Atara Biotherapeutics, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 6. The pillar scores are Audit: 6; Board: 5; Shareholder Rights: 8; Compensation: 7.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 06, 2024 - May 10, 2024
Atara Biotherapeutics, Inc. Earnings Call

Related Tickers

FGEN FibroGen, Inc.
1.1400
-0.87%
 
ALLO Allogene Therapeutics, Inc.
3.4000
-2.02%
 
GTHX G1 Therapeutics, Inc.
4.1000
-0.24%
 
CHRS Coherus BioSciences, Inc.
2.1800
+5.31%
 
MGNX MacroGenics, Inc.
15.41
-1.28%
 
KPTI Karyopharm Therapeutics Inc.
1.1300
-3.42%
 
ADAP Adaptimmune Therapeutics plc
1.0100
+3.41%
 
ACET Adicet Bio, Inc.
2.0000
+2.56%
 
BCAB BioAtla, Inc.
2.1800
+3.56%
 
MCRB Seres Therapeutics, Inc.
0.6246
+11.56%